A novel imaging test for metastatic breast cancer that enables more personalized, precise treatment
No two patients with metastatic breast cancer are alike as the spread of tumors is unique to each patient. Metastatic breast cancer tumors most commonly spread to the liver, brain, bones and/or lungs. Even after treatment, metastatic breast cancer may not go away completely… but in many cases, it can be controlled.
The diagnosis and treatment of metastatic breast cancer can be influenced by the estrogen receptors within the tumors. Until recently, doctors had no way of knowing if all the tumors in a patient with metastatic breast cancer were ER-positive or ER-negative. Since both types can be present, knowing which tumors are ER-positive and which are ER-negative can affect how cancer is treated, and ultimately, outcomes.
Cerianna (fluorine-18-fluorestradiol) is used with whole-body PET/CT imaging to differentiate estrogen receptors in tumors that have metastasized throughout the body. It is FDA approved and is performed at Imaging Healthcare Specialists in addition to biopsy.
Cerianna provide critical information to doctors to help guide treatment recommendations. It enables a more personalized approach to cancer therapy that is not possible with biopsy alone. It can also determine if a treatment is working and if it should be continued.